Top

Published in:

Open Access 01-12-2021 | Cholangiocarcinoma | Research

Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study

Authors: Lu Zou, Xuechuan Li, Xiangsong Wu, Jiujie Cui, Xuya Cui, Xiaoling Song, Tai Ren, Xusheng Han, Yidi Zhu, Huaifeng Li, Wenguang Wu, Xu’an Wang, Wei Gong, Liwei Wang, Maolan Li, Wan Yee Lau, Yingbin Liu

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Gemcitabine plus platinum as the first-line chemotherapy for cholangiocarcinoma (CCA) has limited efficacy. The aim of this study was to evaluate the effectiveness of modified FOLFIRINOX (mFOLFIRINOX) compared to that of gemcitabine plus oxaliplatin (Gemox) for patients with locally advanced or metastatic CCA.

Methods

From January 2016 to December 2019, consecutive patients who were diagnosed with locally advanced or metastatic CCA were treated with either mFOLFIRINOX or Gemox as a first-line chemotherapy. The main endpoint was Progression free survival (PFS). The second endpoints were Overall survival (OS), Disease control rate (DCR) and incidence of severe toxicity (grade 3–4). Tumors were evaluated at baseline and thence every 4–6 weeks. The study was designed and carried out in accordance with the principles of the declaration of Helsinki, approved by the Ethics Committee of Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine (XHEC-D-2020-154) and registered with ClinicalTrials.gov, number NCT04305288 (registration date: 12/03/2020).

Results

Of 49 patients in this study, 27 were in the FOLFIRINOX regimen group and 22 in the Gemox regimen group. There were no significant differences between groups in baseline characteristics. The DCR was 77.8% in the mFOLFIRINOX group and 63.5% in the Gemox group. The corresponding median PFS was 9.9 months (95% confidence interval [CI], 7.3–12.4) in the mFOLFIRINOX group versus 6.4 months (95% CI,3.6–9.2, p = 0.040) in the Gemox group. The corresponding median OS was 15.7 months (95% CI, 12.5–19.0) versus 12.0 months (95% CI, 9.3–14.8, p = 0.099). Significantly more grade 3–4 vomiting occurred in the mFOLFIRINOX than the Gemox groups (7 (25.9%) vs 1 (4.5%), p = 0.044).

Conclusions

First-line mFOLFIRINOX offered more promising results in patients with advanced or metastatic CCA.

Razumilava N, Gores GJ. Classification, diagnosis, and management of cholangiocarcinoma. Clin Gastroenterol Hepatol. 2013;11(1):13–21.e1 quiz e3–4.CrossRefPubMed

Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72(2):353–63. https://doi.org/10.1016/j.jhep.2019.10.009.CrossRefPubMed

Rizzo A, Ricci AD, Brandi G. Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives. Expert Opin Investig Drugs. 2021;30(4):317–24. https://doi.org/10.1080/13543784.2021.1837774.CrossRefPubMed

Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81. https://doi.org/10.1056/NEJMoa0908721.CrossRefPubMed

Fiteni F, Nguyen T, Vernerey D, Paillard MJ, Kim S, Demarchi M, et al. Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: a systematic review. Cancer Med. 2014;3(6):1502–11. https://doi.org/10.1002/cam4.299.CrossRefPubMedPubMedCentral

Fornaro L, Vivaldi C, Cereda S, et al. Second-line chemotherapy in advanced biliary cancer progressed to first-line platinum-gemcitabine combination: a multicenter survey and pooled analysis with published data. J Exp Clin Cancer Res. 2015;34(1):156. https://doi.org/10.1186/s13046-015-0267-x.CrossRefPubMedPubMedCentral

Rizzo A, Brandi G. First-line chemotherapy in advanced biliary tract Cancer ten years after the ABC-02 trial: "and yet it moves!". Cancer Treat Res Commun. 2021;27:100335. https://doi.org/10.1016/j.ctarc.2021.100335.CrossRefPubMed

Valle JW, Borbath I, Khan SA, Huguet F, Gruenberger T, Arnold D, et al. Biliary cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(suppl 5):v28–37. https://doi.org/10.1093/annonc/mdw324.CrossRefPubMed

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817–25. https://doi.org/10.1056/NEJMoa1011923.CrossRefPubMed

10.

Phelip JM, Edeline J, Blanc JF, Barbier E, Michel P, Bourgeois V, et al. Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: study protocol for a randomized controlled multicenter phase II/III study. Dig Liver Dis. 2019;51(2):318–20. https://doi.org/10.1016/j.dld.2018.11.018.CrossRefPubMed

11.

Ulusakarya A, Karaboué A, Ciacio O, Pittau G, Haydar M, Biondani P, et al. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer. BMC Cancer. 2020;20(1):515. https://doi.org/10.1186/s12885-020-07004-y.CrossRefPubMedPubMedCentral

12.

Lamarca A, Palmer DH, Wasan HS, Ross PJ, Ma YT, Arora A, et al. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol. 2021;22(5):690–701. https://doi.org/10.1016/S1470-2045(21)00027-9.CrossRefPubMedPubMedCentral

13.

Adeva J, Sangro B, Salati M, Edeline J, la Casta A, Bittoni A, et al. Medical treatment for cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):123–42. https://doi.org/10.1111/liv.14100.CrossRefPubMed

14.

Kang MJ, Lee JL, Kim TW, Lee SS, Ahn S, Park DH, et al. Randomized phase II trial of S-1 and cisplatin versus gemcitabine and cisplatin in patients with advanced biliary tract adenocarcinoma. Acta Oncol. 2012;51(7):860–6. https://doi.org/10.3109/0284186X.2012.682628.CrossRefPubMed

15.

Yoo C, Han B, Kim HS, Kim KP, Kim D, Jeong JH, et al. Multicenter phase II study of Oxaliplatin, irinotecan, and S-1 as first-line treatment for patients with recurrent or metastatic biliary tract Cancer. Cancer Res Treat. 2018;50(4):1324–30. https://doi.org/10.4143/crt.2017.526.CrossRefPubMedPubMedCentral

16.

Sahai V, Catalano PJ, Zalupski MM, Lubner SJ, Menge MR, Nimeiri HS, et al. Nab-paclitaxel and gemcitabine as first-line treatment of advanced or metastatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(12):1707–12. https://doi.org/10.1001/jamaoncol.2018.3277.CrossRefPubMedPubMedCentral

17.

Conroy T, Hammel P, Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406. https://doi.org/10.1056/NEJMoa1809775.CrossRefPubMed

18.

Ye LF, Ren C, Bai L, Liang JY, Hu MT, Yang H, et al. Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study. Investig New Drugs. 2021;39(3):836–45. https://doi.org/10.1007/s10637-020-01045-7.CrossRef

19.

Belkouz A, De Vos-Geelen J. Mathôt RaA, et al. efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial. Br J Cancer. 2020;122(5):634–9. https://doi.org/10.1038/s41416-019-0698-9.CrossRefPubMedPubMedCentral

20.

Jiang W, Zeng ZC, Tang ZY, Fan J, Sun HC, Zhou J, et al. A prognostic scoring system based on clinical features of intrahepatic cholangiocarcinoma: the Fudan score. Ann Oncol. 2011;22(7):1644–52. https://doi.org/10.1093/annonc/mdq650.CrossRefPubMed

21.

Bergquist JR, Ivanics T, Storlie CB, Groeschl RT, Tee MC, Habermann EB, et al. Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: a national cohort analysis. J Surg Oncol. 2016;114(4):475–82. https://doi.org/10.1002/jso.24381.CrossRefPubMedPubMedCentral

22.

Fang T, Wang H, Wang Y, et al. Clinical significance of preoperative serum CEA, CA125, and CA19-9 levels in predicting the Resectability of cholangiocarcinoma. Dis Markers. 2019;2019:1–7.

23.

Loosen SH, Roderburg C, Kauertz KL, et al. CEA but not CA19–9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma. Sci Rep. 2017;7(1):1–10.CrossRef

24.

Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, et al. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Investig New Drugs. 2018;36(4):732–41. https://doi.org/10.1007/s10637-018-0598-5.CrossRef

25.

Vivaldi C, Caparello C, Musettini G, Pasquini G, Catanese S, Fornaro L, et al. First-line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors. Int J Cancer. 2016;139(4):938–45. https://doi.org/10.1002/ijc.30125.CrossRefPubMed

Title: Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study
Authors: Lu Zou
Xuechuan Li
Xiangsong Wu
Jiujie Cui
Xuya Cui
Xiaoling Song
Tai Ren
Xusheng Han
Yidi Zhu
Huaifeng Li
Wenguang Wu
Xu’an Wang
Wei Gong
Liwei Wang
Maolan Li
Wan Yee Lau
Yingbin Liu
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Cholangiocarcinoma
Cholangiocarcinoma
Cytostatic Therapy
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08549-2

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Development and validation of genomic predictors of radiation sensitivity using preclinical data

Network meta-analysis of eribulin versus other chemotherapies used as second- or later-line treatment in locally advanced or metastatic breast cancer

PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis

Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment

Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer

Risk and outcome of subsequent malignancies after radioactive iodine treatment in differentiated thyroid cancer patients